Every day clinicians make treatment decisions based on their patient’s age. Age is a primary risk factor for development of adverse clinical outcomes, including stroke, cognitive decline, kidney injury, and life-threatening toxicities to chemotherapy.  However, chronological age alone does not take into account a patient’s personal genetics and history.  Instead, in this new era of personalized medicine, measures of a patient’s molecular age have great potential to improve assessment of risk and thereby save lives and reduce healthcare costs.

HealthSpan Diagnostics has developed a proprietary assay that evaluates molecular age through measurement of expression levels of senescence markers, critical regulators of the aging process. Expression levels of senescence markers vary among individuals of the same age, reflecting unique molecular ages. For example, in a study of 170 volunteers, individuals with a chronological age of 50 years, had a 22.5 years of variation in their molecular age.